On this page
What is Rezdiffra (resmetirom)?
Rezdiffra is the brand name for resmetirom, the first medication the FDA approved specifically to treat MASH, the inflamed, scarring form of fatty liver disease. It is a tablet taken once a day, and it is approved for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, stages F2 and F3. Dr. Ihab Herraka evaluates patients for it in the liver program at Digestive & Liver Center of Arkansas in Fort Smith. Resmetirom acts on a thyroid hormone receptor found mainly in liver cells, the one that helps set how the liver handles fat. It is not a thyroid pill and it is not a weight-loss drug. It is approved for use along with diet and exercise, not in place of them. It reached the market through the FDA's accelerated approval pathway on March 14, 2024, meaning approval rested on improvement in the liver findings that predict long-term outcomes, while a longer confirmatory study continues. It was the first drug approved for MASH and liver fibrosis, and it is no longer the only one: semaglutide, at its weight-management dose, has since been approved for the same F2 to F3 group. Whichever is being considered, the staging comes first and the monitoring continues afterward.
Who Rezdiffra is for, and who it is not for
The approved group is narrower than most people expect. It is intended for adults who have:
- MASH: inflammation and liver-cell injury, not simple liver fat on its own
- Fibrosis staged at F2 or F3, described on reports as moderate-to-advanced scarring
- No cirrhosis
- A plan for nutrition, activity and regular follow-up alongside the medication It is not approved once cirrhosis has developed, and it is not the answer when scarring is minimal, at F0 or F1, where treating the metabolic causes, weight, blood sugar, cholesterol, alcohol, is the mainstay. Pregnancy, breastfeeding, other liver conditions and your full medication list are all reviewed before anyone can say yes.
How eligibility is determined
Eligibility is a staging question, and staging cannot be settled by a questionnaire. Here, the sequence is the same for everyone:
- History and bloodwork. Your metabolic history, alcohol use, medications and supplements, plus liver enzymes, platelets, blood sugar and lipids. We also test for viral hepatitis, autoimmune liver disease and iron overload, because those conditions can look the same from the outside and MASH should be confirmed rather than assumed.
- A FIB-4 score. A calculation from your age, platelet count and two liver enzymes that sorts out who needs a closer look.
- FibroScan. A painless ten-minute in-office scan of liver stiffness and liver fat. For most patients it is the test that shows whether the scarring is likely to sit in the F2 to F3 range.
- A liver biopsy, occasionally. Not part of the usual path. Dr. Herraka arranges one when the non-invasive results disagree with each other, or when another liver disease may be present alongside MASH. This is the part a telehealth prescriber cannot do. An online form cannot measure liver stiffness, examine you, or repeat the scan a year later to see whether anything changed. Whether resmetirom fits you is a decision made after your evaluation, never in advance.
Treatment: starting resmetirom and staying on it
Before the first dose. We check baseline liver blood tests and go through your medication list. Statins and some other cholesterol medications may need a dose adjustment when resmetirom is added, and a few combinations are avoided altogether. Taking it. A once-daily tablet you take at home, dosed by body weight: 80 mg for adults under 100 kg, and 100 mg for adults at or above 100 kg. No injection, no infusion, nothing administered in the office. Side effects. Diarrhea and nausea are the most common, tend to appear early, and often settle. Itching, vomiting and abdominal discomfort are also reported, and gallbladder problems have occurred. Liver injury from the medication itself is uncommon, and it is the reason liver blood tests are repeated during treatment. Tell us rather than stopping on your own. Most side effects are managed without abandoning treatment. Be seen promptly if you develop new or worsening itching, right-sided abdominal pain with fever, dark urine, unusual fatigue, or yellowing of the eyes or skin while taking this or any other liver medication. Go to the emergency department for vomiting blood, black tarry stools, an abdomen that is swelling quickly, or new confusion or severe drowsiness. Those point toward advanced liver disease rather than a side effect to wait out, see cirrhosis. Monitoring. Liver blood tests are repeated after you start and periodically after that, and a repeat FibroScan is usually scheduled about a year in. If your labs move the wrong way, the medication is held or stopped. Everything else continues. Resmetirom does not replace the rest of the plan. Weight, blood sugar, cholesterol and alcohol still drive the disease, which is why fatty liver and weight loss are handled in the same office through our medical weight loss program. If you are not a candidate. Treatment does not stop there. Most patients with fatty liver disease are treated through metabolic care, some are better suited to the weight-management medication now approved for MASH, and staging is repeated over time. A liver at F1 today may call for a different conversation in two years.
What to expect at your visit
Bring your medication and supplement bottles, any outside labs, and any ultrasound, CT, MRI or FibroScan reports you already have. Expect a full history, an exam, bloodwork and, where appropriate, a FibroScan at the same visit. You will hear your fibrosis stage in plain language and whether you appear to be a candidate, along with what happens next either way. For most plans no referral is needed.
Cost & insurance
Office visits, bloodwork and FibroScan testing for MASH are billed as ordinary medical care and covered by most plans when they are medically appropriate. We do not post medication prices online, because what you pay depends on your plan, your deductible and where you are in your plan year. Resmetirom requires prior authorization with essentially every insurer, and plans want documentation of the MASH diagnosis and the fibrosis stage before they will consider it. Medicaid and commercial plans commonly grant an initial authorization for a set number of months and then require evidence that the medication is helping before renewing it. Coverage rules differ by plan and change over time on both the Arkansas and Oklahoma side, so our staff verifies the current requirements for your plan, files the paperwork and tells you what is required before therapy starts, though approval is the insurer's decision, and we will not promise an outcome we do not control. Most major carriers are contracted here, along with Medicare and Medicaid on both sides of the state line; the current list sits on our insurance page.
Frequently asked questions
Do I need a FibroScan or a biopsy before starting Rezdiffra?
You need your fibrosis staged, and for most patients a FibroScan with a FIB-4 blood score is enough. Rezdiffra is approved for stages F2 and F3, so a clinician has to establish that your scarring falls in that range and that you do not have cirrhosis. Biopsy is reserved for cases where non-invasive testing is inconclusive or another liver disease is suspected.
Can I take Rezdiffra if I have cirrhosis?
No. Resmetirom is approved for noncirrhotic MASH, meaning stages F2 and F3, and it is not approved once cirrhosis has developed. Care at that stage shifts toward protecting liver function and screening for complications, a different plan, not no plan. If cirrhosis is found during an evaluation, we explain what changes and coordinate ongoing hepatology care.
Can I get Rezdiffra from a telehealth service instead?
Some online services advertise it, but the requirements do not change with the setting: the MASH diagnosis has to be established, the fibrosis staged, cirrhosis excluded, and liver labs monitored over time. A FibroScan is a physical scan rather than a form, so staging and monitoring are in-person work. Being seen locally also means the same physician reads your results and rechecks your liver a year later.
What are the side effects of Rezdiffra?
Diarrhea and nausea are reported most often, usually early in treatment, and they frequently improve with time. Itching, vomiting and abdominal discomfort also occur, and gallbladder problems have been reported. Liver blood tests are monitored during treatment, and the medication is held or stopped if they suggest liver injury.
Will my insurance cover Rezdiffra?
It depends on your plan, and prior authorization comes first in essentially every case. Insurers typically want proof of the MASH diagnosis, documentation of F2 to F3 fibrosis, and evidence that diet and exercise are part of your care. Our staff prepares and submits that request, appeals when necessary, and tells you what your plan has said before treatment begins. Rezdiffra is filled by a specialty pharmacy your plan works with rather than at our clinic, and we help you set that up once it is approved.
Do I still need to lose weight if I take Rezdiffra?
Yes. Resmetirom is approved for use along with diet and exercise rather than as a substitute for them, and the metabolic drivers behind MASH continue whether or not you are on medication. Weight, blood sugar and alcohol remain the levers that matter most. Because Dr. Herraka is board-certified in gastroenterology, internal medicine and obesity medicine, the liver disease and the weight driving it are treated in the same office rather than in two.
Ask about Rezdiffra eligibility in Fort Smith
If you have been told you have MASH, NASH or liver fibrosis and want to know whether resmetirom is an option for you, the first step is having your liver staged. Call Digestive & Liver Center of Arkansas at (479) 242-2888 or request an appointment. The clinic is at 3416 Old Greenwood Rd, Fort Smith, AR 72903, Monday through Friday, 8:00 to 5:00, and we see patients from across the River Valley and from Poteau, Sallisaw and eastern Oklahoma, where Oklahoma Medicaid is accepted. See the rest of our liver program.